Letter to the editor
Allergen immunotherapy: No evidence of infectious risk

https://doi.org/10.1016/j.jaci.2016.03.021Get rights and content

References (9)

There are more references available in the full text version of this article.

Cited by (12)

  • The prediction models of anaphylactic disease

    2021, Informatics in Medicine Unlocked
    Citation Excerpt :

    The saturated IgE may prevent further fluctuations of allergic positive rates and frequencies as well. This conclusion also corresponds to other literatures about allergen immunotherapy [72–74]. As for deep learning model, we can obtain another figure in the 3D coordinate system as shown in Fig. 9, where the exponential coefficients are related to the potential capacity of plasma cell division and specific IgE production.

  • The infection rate of intralesional triamcinolone and the safety of compounding in dermatology for intradermal and subcutaneous injection: A retrospective medical record review

    2020, Journal of the American Academy of Dermatology
    Citation Excerpt :

    Researchers within allergy and otolaryngology have demonstrated the safety of in-office immunotherapy preparation under clean technique. In the allergy literature, 2 prospective (136 in-office vials and 320 in-office immunotherapy injections) and 2 retrospective (26,795 and >130,000 subcutaneous allergen in-office immunotherapy injections) studies revealed negative vial cultures and no infections.13-15 To our knowledge, infection rates of compounded medications for dermatologic use have not been assessed.

  • Mining social media data to assess the risk of skin and soft tissue infections from allergen immunotherapy

    2019, Journal of Allergy and Clinical Immunology
    Citation Excerpt :

    We identified a small number of posts describing a possible AIT-related SSTI using informatics methods (0.02%; 95% CI, 0.005%-0.043%). This study confirms findings to date from traditional studies that have found a negligible risk of infection for patients receiving AIT.6,10-12,14 Specifically, 1 previous retrospective study of 272 patients on AIT did not identify a single patient with SSTI from AIT, nor any patient with a fever, discharge from the injection site, or cellulitis.14

View all citing articles on Scopus

Supported by the National Institutes of Health (grant T32 HL116275 to D.S.B.).

Disclosure of potential conflict of interest: D. S. Balekian has received a grant from the National Institutes of Health (T32 HL116275). The rest of the authors declare that they have no relevant conflicts of interest.

View full text